Response and biological subtype of myeloma are independent prognostic factors and combine to define outcome after high-dose therapy.
Division of Molecular Pathology, Haemato-Oncology Research Unit, The Institute of Cancer Research, London, UK.
Annamaria
A
Brioli
Kevin D
KD
Boyd
Martin F
MF
Kaiser
Charlotte
C
Pawlyn
Ping
P
Wu
Walter M
WM
Gregory
Roger
R
Owen
Fiona M
FM
Ross
Graham H
GH
Jackson
Michele
M
Cavo
Faith E
FE
Davies
Gareth J
GJ
Morgan
D002877:Chromosomes, Human / Q000235:genetics; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D008297:Male; D008954:Models, Biological; D009101:Multiple Myeloma / Q000235:genetics / Q000401:mortality* / Q000473:pathology / Q000628:therapy*; D033581:Stem Cell Transplantation; D015996:Survival Rate; D013997:Time Factors; D014178:Translocation, Genetic / Q000235:genetics; D014184:Transplantation, Homologous